AU3072099A - Vascular endothelial growth factor 2 - Google Patents

Vascular endothelial growth factor 2 Download PDF

Info

Publication number
AU3072099A
AU3072099A AU30720/99A AU3072099A AU3072099A AU 3072099 A AU3072099 A AU 3072099A AU 30720/99 A AU30720/99 A AU 30720/99A AU 3072099 A AU3072099 A AU 3072099A AU 3072099 A AU3072099 A AU 3072099A
Authority
AU
Australia
Prior art keywords
polypeptide
vegf
sequence
polypeptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30720/99A
Other languages
English (en)
Inventor
Liang Cao
Jing-Shan Hu
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/042,105 external-priority patent/US6040157A/en
Priority claimed from US09/107,997 external-priority patent/US7186688B1/en
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU3072099A publication Critical patent/AU3072099A/en
Priority to AU2003264585A priority Critical patent/AU2003264585A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
AU30720/99A 1998-03-13 1999-03-10 Vascular endothelial growth factor 2 Abandoned AU3072099A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003264585A AU2003264585A1 (en) 1998-03-13 2003-11-27 Vascular Endothelial Growth Factor 2

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09042105 1998-03-13
US09/042,105 US6040157A (en) 1994-03-08 1998-03-13 Vascular endothelial growth factor 2
US09107997 1998-06-30
US09/107,997 US7186688B1 (en) 1994-03-08 1998-06-30 Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
PCT/US1999/005021 WO1999046364A1 (fr) 1998-03-13 1999-03-10 Facteur de croissance endothelial vasculaire 2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003264585A Division AU2003264585A1 (en) 1998-03-13 2003-11-27 Vascular Endothelial Growth Factor 2

Publications (1)

Publication Number Publication Date
AU3072099A true AU3072099A (en) 1999-09-27

Family

ID=26718873

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30720/99A Abandoned AU3072099A (en) 1998-03-13 1999-03-10 Vascular endothelial growth factor 2

Country Status (7)

Country Link
EP (1) EP1062319A4 (fr)
JP (1) JP2002505873A (fr)
KR (1) KR20010034576A (fr)
CN (1) CN1299407A (fr)
AU (1) AU3072099A (fr)
CA (1) CA2322748A1 (fr)
WO (1) WO1999046364A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414016A1 (fr) 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Facteur 2 de croissance vasculaire endotheliale
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
ATE242809T1 (de) 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
EP1017421B1 (fr) * 1997-03-07 2005-05-25 The Wistar Institute Of Anatomy And Biology Utilisation de vecteurs adénoviraux exprimant VEGF ou PDGF pour SOIGNER LES blessures TISSULAIRES ET D'INDUIRE L'HYPERVASCULARITE DANS DES TISSUS de MAMMIFERES
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
WO2000058511A1 (fr) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Dosage et therapie pour les troubles lymphatiques impliquant la tyrosine kinase flt4 (vegfr-3)
ES2551160T3 (es) 2000-04-12 2015-11-16 Vib Vzw Uso de VEGF y homólogos para tratar trastornos neurológicos
NZ518077A (en) 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
WO2003018752A2 (fr) 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology Culture organotypique intestinale et son utilisation
WO2003081201A2 (fr) * 2002-03-21 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Marqueurs de cellules sanguines peripheriques utiles pour le diagnostic de la sclerose en plaques et procedes et trousses comprenant de tels marqueurs
EP1575548B1 (fr) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions et methodes visant a favoriser l'excroissance neuronale
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2004247026B2 (en) * 2003-05-16 2009-09-24 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of CNS
US8226941B2 (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
SI1755647T1 (sl) 2004-05-27 2011-01-31 Vib Vzw Zdravljenje amiotrofiäśne lateralne skleroze
EP1869075B1 (fr) 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Methodes et compostions anti-angiogeniques
WO2007038548A2 (fr) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions et procedes d'utilisation de mutants des chondroitinases abci
CN100448892C (zh) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 抗肿瘤血管内皮生长因子受体vegf－r2抗原及其编码基因与应用
EP2450442B1 (fr) 2006-10-10 2017-07-19 Acorda Therapeutics, Inc. Compositions et procédés d'utilisation de mutants des chondroïtinase abci

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414016A1 (fr) * 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Facteur 2 de croissance vasculaire endotheliale
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
WO1998033917A1 (fr) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Proteine et gene du facteur de croissance vasculaire endothelial c (vegf-c), mutants de ce dernier et utilisations
ATE242809T1 (de) * 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
AU1116297A (en) * 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
ES2212121T3 (es) * 1996-08-13 2004-07-16 Human Genome Sciences, Inc. Mutantes de factor-2 de crecimiento queranocitico (kgf-2 o factor -12 de crecimiento fibroblastico, fgf-12).
KR20010020259A (ko) * 1997-04-25 2001-03-15 컬래터럴 테러퓨틱스 말단이 잘린 ｖｅｇｆ-관련 단백질

Also Published As

Publication number Publication date
KR20010034576A (ko) 2001-04-25
WO1999046364A9 (fr) 1999-11-18
EP1062319A1 (fr) 2000-12-27
CA2322748A1 (fr) 1999-09-16
CN1299407A (zh) 2001-06-13
WO1999046364A1 (fr) 1999-09-16
EP1062319A4 (fr) 2003-04-23
JP2002505873A (ja) 2002-02-26

Similar Documents

Publication Publication Date Title
US6734285B2 (en) Vascular endothelial growth factor 2 proteins and compositions
US7153942B2 (en) Vascular endothelial growth factor 2
US20060057117A1 (en) Vascular endothelial growth factor 2
AU3072099A (en) Vascular endothelial growth factor 2
AU2002257142B2 (en) Vascular endothelial growth factor 2
US20060025331A1 (en) Vascular endothelial growth factor 2
US20050059117A1 (en) Vascular endothelial growth factor 2
AU2002257142A1 (en) Vascular endothelial growth factor 2
US20030170786A1 (en) Vascular endothelial growth factor 2
WO2003097660A1 (fr) Facteur de croissance endothelial vasculaire 2
AU2003264585A1 (en) Vascular Endothelial Growth Factor 2
MXPA00008920A (en) Vascular endothelial growth factor 2

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted